Grant Private Wealth Management Inc Takes $306,000 Position in Johnson & Johnson (NYSE:JNJ)

Grant Private Wealth Management Inc bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,113 shares of the company's stock, valued at approximately $306,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $32,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $4.54 during mid-day trading on Thursday, reaching $159.90. 13,243,050 shares of the stock traded hands, compared to its average volume of 7,757,538. The stock has a market capitalization of $385.33 billion, a PE ratio of 24.04, a PEG ratio of 2.56 and a beta of 0.47. The business has a 50-day moving average of $159.63 and a 200 day moving average of $156.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the company earned $2.29 EPS. The firm's revenue was up 5.3% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JNJ. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.33.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.